Norman T. Ilowite - Concepedia

Author

Norman T. Ilowite

Albert Einstein College of Medicine ORCID

Also Known As

Johannes-Peter Haas, Kathleen A Fox, Maria Ibarra, N ILOWITE, N Ilowite, N T Ilowite, N. Ilowite, N. T. Ilowite, N.T Ilowite, N.T. ILOWITE

194

Publications

12.4K

Citations

H-Index

Concepts

All Affiliations

Albert Einstein College of Medicine Cincinnati Children's Hospital Medical Center Schneider Children's Hospital Children's Hospital at Montefiore Seattle Children's Hospital

About

Norman T. Ilowite is an author at Albert Einstein College of Medicine specializing in medicine, rheumatology, and pediatrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	27	1.8K
2	Public Health	5	5	346
3	Allergy	4	4	78
4	Health Sciences	2	2	220
5	Education	1	1	14

Norman T. Ilowite

Publications

10.5K

Citations

H-Index

Page 1

	Year	Citations
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis Daniel J. Lovell, Edward H. Giannini, Andreas Reiff, New England Journal of Medicine	2000	1.2K
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative Angelo Ravelli, Francesca Minoia, Sergio Davì, Arthritis & Rheumatology	2015	742
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus Alberto Martini, Angelo Ravelli, Tadej Avčin, The Journal of Rheumatology	2018	514
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series Peter A. Nigrović, Melissa L. Mannion, Femke H. M. Prince, Arthritis & Rheumatism	2010	458
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis Angelo Ravelli, Francesca Minoia, Sergio Davì, Annals of the Rheumatic Diseases	2016	380
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis Daniel J. Lovell, Andreas Reiff, Norman T. Ilowite, Arthritis & Rheumatism	2008	317
The diagnostic significance of soluble CD163 and soluble interleukin‐2 receptor α‐chain in macrophage activation syndrome and untreated new‐onset systemic juvenile idiopathic arthritis Jack Bleesing, Anne E. Prada, David Siegel, Arthritis & Rheumatism	2007	315
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis Carol A. Wallace, Edward H. Giannini, Steven J. Spalding, Arthritis & Rheumatism	2011	304
2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications Sarah Ringold, Pamela F. Weiss, Timothy Beukelman, Arthritis Care & Research	2013	299
Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trial Daniel J. Lovell, Edward H. Giannini, Andreas Reiff, Arthritis & Rheumatism	2003	254

Page 1